Clara Baldari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Clara Baldari has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alessandra Invidia
Department of Experimental Medicine University of Salento Lecce Italy
1 shared publication- Biagio De Angelis
Department of Onco‐Haematology and Cell and Gene Therapy Bambino Gesù Children's Hospital IRCCS Rome Italy
1 shared publication Claudia De Stradis
Department of Experimental Medicine University of Salento Lecce Italy
1 shared publicationClaudia Leone
Tecnomed Puglia ‐ Tecnopolo Per La Medicina Di Precisione (Biotech Lecce Hub) Lecce Italy
1 shared publicationConcetta Quintarelli
Department of Clinical Medicine and Surgery Federico II University of Naples Naples Italy
1 shared publication- Franco Locatelli
Department of Pediatric Hematology/Oncology, Cell and Gene Therapy IRCCS Bambino Gesù Children's Hospital Rome Italy
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (37) , e71640
From Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery
Nonviral gene therapy reached unprecedented clinical prominence, with the approval of lipid nanoparticles (LNPs). Yet, their success remains largely confined to a narrow range of applications and tissues, which reflects the inherent functional constraints based on formulation optimization to overcome intrinsically complex physiological barriers. In contrast, biological membranes evolved to integrate immune evasion, targeting, intracellular trafficking, and membrane fusion within a single functional interface. In this review, we provide a mechanistic comparison between membrane‐derived vesicles (MDVs) and hybrid biomimetic systems. We critically examine MDVs from different biological sources, highlighting their unique advantages for gene delivery applications. We also focus on hybrid systems, which merge the biological functionality of naturally derived membranes with the design control of synthetic nanovectors to address key limitations such as inefficient cytosolic release, poor targeting specificity, and transfection of hard‐to‐engineer cells. This review provides a biologically informed roadmap for designing efficient gene delivery vectors, proposing membrane‐integrated nanovesicles (NVs) as “living interfaces” for non‐viral gene therapy.
- 25 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (37) , e71640
Open AccessFrom Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery
Nonviral gene therapy reached unprecedented clinical prominence, with the approval of lipid nanoparticles (LNPs). Yet, their success remains largely confined to a narrow range of applications and tissues, which reflects the inherent functional constraints based on formulation optimization to overcome intrinsically complex physiological barriers. In contrast, biological membranes evolved to integrate immune evasion, targeting, intracellular trafficking, and membrane fusion within a single functional interface. In this review, we provide a mechanistic comparison between membrane‐derived vesicles (MDVs) and hybrid biomimetic systems. We critically examine MDVs from different biological sources, highlighting their unique advantages for gene delivery applications. We also focus on hybrid systems, which merge the biological functionality of naturally derived membranes with the design control of synthetic nanovectors to address key limitations such as inefficient cytosolic release, poor targeting specificity, and transfection of hard‐to‐engineer cells. This review provides a biologically informed roadmap for designing efficient gene delivery vectors, proposing membrane‐integrated nanovesicles (NVs) as “living interfaces” for non‐viral gene therapy.